• Genetic TherapyEnrolling

  Study of 4D-710 in Adults with Cystic Fibrosis , protocol number 4DMT 4D-710-C001 (Part 1 and 2)

  This study will test the safety and tolerability of 4D-710, an investigational gene therapy, in adults with CF who are not eligible for or are unable to tolerate CFTR modulator therapy.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    22

  • Length of Participation:

    1 years

• Restore CFTR ProteinEnrolling

  Study of VX-828 in combination with Tezacaftor and Deutivacaftor in healthy participants and in adults with cystic fibrosis. , protocol number Vertex VX23-828-001 Phase 1 Part E

  Part E of this study will look at the safety and tolerability of VX-828 in combination with Tezacaftor and Deutivacaftor in adults with CF. The drug combination is intended to help CFTR function closer to normal. 

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    12

  • Length of Participation:

    4 months

• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InfectiveEnrolling

  Study to evaluate two antibiotic treatment approaches for the management of outpatient pulmonary exacerbations in children 3 to 18 years old. , protocol number STOP PEDS 2.0 RCT Main Cohort

  The STOP PEDS study will evaluate the safety and effectiveness of two antibiotic treatment approaches for mild pulmonary exacerbations, which are treated at home, in children with CF.

  • Age:

    3 Years to 18 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50% or greater

  • Number of Visits:

    6

  • Length of Participation:

    0 days

• Nutritional-GIEnrolling

  Study to evaluate ANG003 in people with CF ages 12 and older , protocol number Anagram ANG003-25-201

  This study will assess the safety and effectiveness of ANG003, a pancreatic enzyme replacement therapy, also known as “enzymes” or “enzyme therapy”, to see whether it works as well as the approved enzyme therapy Creon.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    6

  • Length of Participation:

    3 months

• ObservationalEnrolling

  SEND-CF: Study to identify new ways to diagnose harmful bacteria in the lungs of people with CF ages 16 and older , protocol number SENDCF-OB-25

  The SEND-CF study will gather health information and samples from people with CF to find new and better ways to spot harmful bacteria in the lungs.

  • Age:

    16 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    1

  • Length of Participation:

    1 days

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.